To date, revumenib stands as the most clinically developed small molecule menin inhibitor, demonstrating promising results in the first in-human phase I/II clinical trials including relapsed or refractory pediatric and adult KMT2A-rearranged or NPM1-mutated acute leukemia patients [32]. This evidence concerns the gene KMT2A and acute leukemia.